Your browser doesn't support javascript.
loading
STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion.
Gotthardt, Dagmar; Putz, Eva M; Grundschober, Eva; Prchal-Murphy, Michaela; Straka, Elisabeth; Kudweis, Petra; Heller, Gerwin; Bago-Horvath, Zsuzsanna; Witalisz-Siepracka, Agnieszka; Cumaraswamy, Abbarna A; Gunning, Patrick T; Strobl, Birgit; Müller, Mathias; Moriggl, Richard; Stockmann, Christian; Sexl, Veronika.
Afiliación
  • Gotthardt D; Department for Biomedical Sciences, Institute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, Vienna, Austria.
  • Putz EM; Department for Biomedical Sciences, Institute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, Vienna, Austria.
  • Grundschober E; Department for Biomedical Sciences, Institute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, Vienna, Austria.
  • Prchal-Murphy M; Department for Biomedical Sciences, Institute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, Vienna, Austria.
  • Straka E; Department for Biomedical Sciences, Institute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, Vienna, Austria.
  • Kudweis P; Department for Biomedical Sciences, Institute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, Vienna, Austria.
  • Heller G; Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria. Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Bago-Horvath Z; Clinical Institute of Pathology, Medical University of Vienna (MUV), Vienna, Austria.
  • Witalisz-Siepracka A; Department for Biomedical Sciences, Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria.
  • Cumaraswamy AA; Department of Chemistry, University of Toronto Mississauga, Mississauga, Ontario, Canada.
  • Gunning PT; Department of Chemistry, University of Toronto Mississauga, Mississauga, Ontario, Canada.
  • Strobl B; Department for Biomedical Sciences, Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria.
  • Müller M; Department for Biomedical Sciences, Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria.
  • Moriggl R; Department for Biomedical Sciences, Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria. Ludwig Boltzmann Institute for Cancer Research (LBI-CR), Vienna, Austria.
  • Stockmann C; PARCC Paris - Centre de recherche Cardiovasculaire à l'HEGP Inserm - UMR 970, Paris, France.
  • Sexl V; Department for Biomedical Sciences, Institute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, Vienna, Austria. veronika.sexl@vetmeduni.ac.at.
Cancer Discov ; 6(4): 414-29, 2016 Apr.
Article en En | MEDLINE | ID: mdl-26873347
UNLABELLED: Natural killer (NK) cells are tightly regulated by the JAK-STAT signaling pathway and cannot survive in the absence of STAT5. We now report that STAT5-deficient NK cells can be rescued by overexpression of BCL2. Our experiments define STAT5 as a master regulator of NK-cell proliferation and lytic functions. Although NK cells are generally responsible for killing tumor cells, the rescued STAT5-deficient NK cells promote tumor formation by producing enhanced levels of the angiogenic factor VEGFA. The importance of VEGFA produced by NK cells was verified by experiments with a conditional knockout of VEGFA in NK cells. We show that STAT5 normally represses the transcription of VEGFA in NK cells, in both mice and humans. These findings reveal that STAT5-directed therapies may have negative effects: In addition to impairing NK-cell-mediated tumor surveillance, they may even promote tumor growth by enhancing angiogenesis. SIGNIFICANCE: The importance of the immune system in effective cancer treatment is widely recognized. We show that the new signal interceptors targeting the JAK-STAT5 pathway may have dangerous side effects that must be taken into account in clinical trials: inhibiting JAK-STAT5 has the potential to promote tumor growth by enhancing NK-cell-mediated angiogenesis.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Células Asesinas Naturales / Transformación Celular Neoplásica / Factor de Transcripción STAT5 / Vigilancia Inmunológica / Neoplasias Tipo de estudio: Prognostic_studies / Screening_studies Límite: Animals / Humans Idioma: En Revista: Cancer Discov Año: 2016 Tipo del documento: Article País de afiliación: Austria

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Células Asesinas Naturales / Transformación Celular Neoplásica / Factor de Transcripción STAT5 / Vigilancia Inmunológica / Neoplasias Tipo de estudio: Prognostic_studies / Screening_studies Límite: Animals / Humans Idioma: En Revista: Cancer Discov Año: 2016 Tipo del documento: Article País de afiliación: Austria